Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocr...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Binghe, Zhang, Qingyuan, Hu, Xichun, Li, Qing, Sun, Tao, Li, Wei, Ouyang, Quchang, Wang, Jingfen, Tong, Zhongsheng, Yan, Min, Li, Huiping, Zeng, Xiaohua, Shan, Changping, Wang, Xian, Yan, Xi, Zhang, Jian, Zhang, Yue, Wang, Jiani, Zhang, Liang, Lin, Ying, Feng, Jifeng, Chen, Qianjun, Huang, Jian, Zhang, Lu, Yang, Lisong, Tian, Ying, Shang, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213795/
https://www.ncbi.nlm.nih.gov/pubmed/37250148
http://dx.doi.org/10.1016/j.apsb.2023.02.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213795/
https://www.ncbi.nlm.nih.gov/pubmed/37250148
http://dx.doi.org/10.1016/j.apsb.2023.02.001

Ejemplares similares